HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
ID: 342928Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $750K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/342928

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-053.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)." This grant aims to support action-oriented research that translates evidence-based practices into effective care systems for individuals facing addiction, with a focus on reducing overdose deaths through stigma-free, patient-centered approaches and outreach to underserved populations. The initiative is critical for enhancing the quality and accessibility of addiction care, emphasizing innovative strategies and stakeholder collaboration aligned with the HHS Overdose Prevention Strategy. Interested applicants can apply for funding up to $750,000, with a total anticipated funding of up to $15 million for related projects, and must submit their applications by March 20, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the full announcement at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-053.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    RFA-DA-23-053-Full-Announcement.html
    RFA-DA-23-053.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has initiated funding opportunities under the HEAL Initiative to address the ongoing overdose crisis. The specific funding announcement, RFA-DA-23-053, seeks applications for action-oriented research aimed at translating evidence-based practices into tangible care systems for individuals experiencing addiction. The initiative addresses critical barriers to reducing overdose deaths, emphasizing stigma-free, patient-centered approaches and outreach to underserved populations. Funding aims to facilitate projects requiring preparatory work, such as stakeholder engagement and infrastructure development, progressing through an R61 phase (up to 2 years) followed by an R33 phase (up to 5 years). Up to $15 million is anticipated for both this and a related companion FOA. Applications must demonstrate innovative strategies, stakeholder collaboration, and alignment with the HHS Overdose Prevention Strategy pillars, focusing on harm reduction, recovery support, and treatment of substance use disorders. The initiative reflects a commitment to enhancing the quality and accessibility of addiction care, fostering research that prioritizes equitable health outcomes.
    Similar Opportunities
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the HEAL Initiative aimed at enhancing the implementation of preventive services for substance use disorders, specifically focusing on opioid misuse. This initiative invites applications for research that addresses gaps in the dissemination and implementation of prevention services, with a phased R61/R33 award mechanism allowing for up to six years of support, contingent on the successful completion of preliminary milestones. The overarching goal is to establish a sustainable prevention infrastructure that effectively reduces risks associated with substance use, emphasizing equity and community involvement in the research process. Interested applicants can find more information and apply by the deadline of January 16, 2026, with a projected funding amount of $4.65 million for the 2024 fiscal year. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-066.html.
    HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity under the HEAL Initiative, aimed at enhancing the implementation and sustainability of substance use preventive services. This initiative seeks to address the critical gaps between effective prevention research and its practical application, particularly in combating the opioid crisis, by soliciting applications for projects that demonstrate preliminary data and focus on strengthening prevention infrastructure. With approximately $4.65 million available for funding, grants can support projects for up to five years, with annual budget requests advised to remain under $800,000. Interested applicants must submit their proposals by January 16, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.